Trial · NCT02850406
Participant flow96
How many started, completed or left each group, period by period.
41 to 60 of 96
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 0 | |
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 0 | |
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part B: Voxelotor 900 mg QD | 3 | |
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part B: Voxelotor 1500 mg QD | 3 | |
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part C: Participants Aged 4 to 11 Years: Voxelotor 1500 mg QD | 0 | |
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part C: Participants Aged 12 to 17 Years: Voxelotor 1500 mg QD | 0 | |
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | 0 | |
| Part B (Up to 28 Weeks) | NOT COMPLETED | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | 0 | |
| Part C (Up to 52 Weeks) | STARTED | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 0 | |
| Part C (Up to 52 Weeks) | STARTED | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 0 | |
| Part C (Up to 52 Weeks) | STARTED | Part B: Voxelotor 900 mg QD | 0 | |
| Part C (Up to 52 Weeks) | STARTED | Part B: Voxelotor 1500 mg QD | 0 | |
| Part C (Up to 52 Weeks) | STARTED | Part C: Participants Aged 4 to 11 Years: Voxelotor 1500 mg QD | 51 | |
| Part C (Up to 52 Weeks) | STARTED | Part C: Participants Aged 12 to 17 Years: Voxelotor 1500 mg QD | 11 | |
| Part C (Up to 52 Weeks) | STARTED | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | 0 | |
| Part C (Up to 52 Weeks) | STARTED | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | 0 | |
| Part C (Up to 52 Weeks) | COMPLETED | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 0 | |
| Part C (Up to 52 Weeks) | COMPLETED | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 0 | |
| Part C (Up to 52 Weeks) | COMPLETED | Part B: Voxelotor 900 mg QD | 0 | |
| Part C (Up to 52 Weeks) | COMPLETED | Part B: Voxelotor 1500 mg QD | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02850406/flow?page=3